Intra-Cellular Return On Equity

ITCI
 Stock
  

USD 53.57  3.45  6.05%   

Intra-Cellular Ther fundamentals help investors to digest information that contributes to Intra-Cellular Ther's financial success or failures. It also enables traders to predict the movement of Intra-Cellular Stock. The fundamental analysis module provides a way to measure Intra-Cellular Ther's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intra-Cellular Ther stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
The current Average Equity is estimated to decrease to about 443.8 M.

Intra-Cellular Return On Equity Analysis

Intra-Cellular Ther's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
 2021 2022 (projected)
Interest Expense33.1 K33.97 K
Gross Profit75.77 M81.75 M
Return on Equity 
 = 
Net Income 
Total Equity 
X
100 
More About Return On Equity | All Equity Analysis

Current Intra-Cellular Ther Return On Equity

    
  (43.21) %  
Most of Intra-Cellular Ther's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra-Cellular Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Intra-Cellular Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Intra-Cellular Ther is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Return On Equity. Since Intra-Cellular Ther's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intra-Cellular Ther's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intra-Cellular Ther's interrelated accounts and indicators.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Compare to competition

Intra-Cellular Shareholders Equity

Shareholders Equity

380.55 Million

Intra-Cellular Ther Shareholders Equity is most likely to increase significantly in the upcoming years. The last year's value of Shareholders Equity was reported at 417.89 Million
Based on the latest financial disclosure, Intra-Cellular Ther has a Return On Equity of -43.21%. This is 80.27% higher than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is notably higher than that of the company.

Intra-Cellular Ther Current Valuation Drivers

We derive many important indicators used in calculating different scores of Intra-Cellular Ther from analyzing Intra-Cellular Ther's financial statements. These drivers represent accounts that assess Intra-Cellular Ther's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intra-Cellular Ther's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(2 M)(2.13 M)(447.64 K)(591.09 K)(554.93 K)(598.74 K)
Revenue Per Employee7.85 K5.02 K18459.4 K163.68 K176.6 K
Average Assets381.88 M400.13 M296.14 M602.7 M586.77 M498.29 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings before Tax(98.83 M)(155.13 M)(147.72 M)(226.99 M)(284.12 M)(291.6 M)
Average Equity366.64 M371.23 M241.82 M544.06 M517.6 M443.81 M
Enterprise Value737.94 M553.56 M1.82 B2.28 B4.18 B4.51 B
Free Cash Flow(81.22 M)(118.56 M)(128.68 M)(230.34 M)(259.87 M)(266.71 M)
Invested Capital419.49 M265.96 M130.47 M648.16 M368.21 M332.89 M
Invested Capital Average333.71 M306.89 M193.88 M423.85 M451.48 M372.11 M
Market Capitalization790.28 M623.33 M1.9 B2.55 B4.26 B4.6 B
Tangible Asset Value471.49 M357.21 M251.19 M717.31 M489.92 M435.39 M
Working Capital455.01 M319.14 M194.1 M654.05 M413.92 M379.9 M

Intra-Cellular Fundamentals

About Intra-Cellular Ther Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra-Cellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra-Cellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra-Cellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Average Equity517.6 M443.8 M
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Intra-Cellular Ther Investors Sentiment

The influence of Intra-Cellular Ther's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intra-Cellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Intra-Cellular Ther's public news can be used to forecast risks associated with investment in Intra-Cellular. The trend in average sentiment can be used to explain how an investor holding Intra-Cellular can time the market purely based on public headlines and social activities around Intra-Cellular Ther. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Intra-Cellular Ther's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intra-Cellular Ther's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intra-Cellular Ther's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Intra-Cellular Ther.

Intra-Cellular Ther Implied Volatility

    
  91.87  
Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Altman Z Score analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.4 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.